ES2626150T3 - Inhibidores de virus flaviviridae - Google Patents
Inhibidores de virus flaviviridae Download PDFInfo
- Publication number
- ES2626150T3 ES2626150T3 ES11700988.6T ES11700988T ES2626150T3 ES 2626150 T3 ES2626150 T3 ES 2626150T3 ES 11700988 T ES11700988 T ES 11700988T ES 2626150 T3 ES2626150 T3 ES 2626150T3
- Authority
- ES
- Spain
- Prior art keywords
- optionally substituted
- substituted
- alkyl
- membered
- alkynyl
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
- 239000003112 inhibitor Substances 0.000 title claims description 21
- 241000710781 Flaviviridae Species 0.000 title claims description 13
- 125000001072 heteroaryl group Chemical group 0.000 claims abstract description 48
- 125000000623 heterocyclic group Chemical group 0.000 claims abstract description 45
- 150000001875 compounds Chemical class 0.000 claims abstract description 36
- 125000003710 aryl alkyl group Chemical group 0.000 claims abstract description 34
- 125000004400 (C1-C12) alkyl group Chemical group 0.000 claims abstract description 27
- 125000000304 alkynyl group Chemical group 0.000 claims abstract description 20
- 125000003342 alkenyl group Chemical group 0.000 claims abstract description 19
- 125000003118 aryl group Chemical group 0.000 claims abstract description 18
- 125000004446 heteroarylalkyl group Chemical group 0.000 claims abstract description 18
- 229910052739 hydrogen Inorganic materials 0.000 claims abstract description 18
- 150000003839 salts Chemical class 0.000 claims abstract description 18
- 125000004169 (C1-C6) alkyl group Chemical group 0.000 claims abstract description 17
- 125000005913 (C3-C6) cycloalkyl group Chemical group 0.000 claims abstract description 15
- 125000000882 C2-C6 alkenyl group Chemical group 0.000 claims abstract description 15
- 125000003601 C2-C6 alkynyl group Chemical group 0.000 claims abstract description 15
- 125000006652 (C3-C12) cycloalkyl group Chemical group 0.000 claims abstract description 14
- 125000005915 C6-C14 aryl group Chemical group 0.000 claims abstract description 14
- 125000003545 alkoxy group Chemical group 0.000 claims abstract description 11
- 125000004104 aryloxy group Chemical group 0.000 claims abstract description 9
- 229910052736 halogen Inorganic materials 0.000 claims abstract description 9
- 150000002367 halogens Chemical class 0.000 claims abstract description 9
- 125000005553 heteroaryloxy group Chemical group 0.000 claims abstract description 9
- 125000005844 heterocyclyloxy group Chemical group 0.000 claims abstract description 9
- 125000003320 C2-C6 alkenyloxy group Chemical group 0.000 claims abstract description 8
- 101000599004 Homo sapiens Olfactory receptor 3A1 Proteins 0.000 claims abstract description 8
- 102100037784 Olfactory receptor 3A1 Human genes 0.000 claims abstract description 8
- 125000005133 alkynyloxy group Chemical group 0.000 claims abstract description 8
- 125000000000 cycloalkoxy group Chemical group 0.000 claims abstract description 8
- 125000006714 (C3-C10) heterocyclyl group Chemical group 0.000 claims abstract description 6
- -1 tetrahydro-2H-pyranyl Chemical group 0.000 claims description 29
- 241000711549 Hepacivirus C Species 0.000 claims description 19
- 238000011282 treatment Methods 0.000 claims description 18
- 125000005842 heteroatom Chemical group 0.000 claims description 14
- 229910052760 oxygen Inorganic materials 0.000 claims description 14
- 241000700605 Viruses Species 0.000 claims description 11
- 229910052717 sulfur Inorganic materials 0.000 claims description 10
- 230000009385 viral infection Effects 0.000 claims description 9
- 208000036142 Viral infection Diseases 0.000 claims description 8
- 239000003814 drug Substances 0.000 claims description 8
- IWUCXVSUMQZMFG-AFCXAGJDSA-N Ribavirin Chemical compound N1=C(C(=O)N)N=CN1[C@H]1[C@H](O)[C@H](O)[C@@H](CO)O1 IWUCXVSUMQZMFG-AFCXAGJDSA-N 0.000 claims description 6
- 125000004429 atom Chemical group 0.000 claims description 6
- 239000000203 mixture Substances 0.000 claims description 6
- 229960000329 ribavirin Drugs 0.000 claims description 6
- HZCAHMRRMINHDJ-DBRKOABJSA-N ribavirin Natural products O[C@@H]1[C@H](O)[C@@H](CO)O[C@H]1N1N=CN=C1 HZCAHMRRMINHDJ-DBRKOABJSA-N 0.000 claims description 6
- 125000000753 cycloalkyl group Chemical group 0.000 claims description 5
- 125000003718 tetrahydrofuranyl group Chemical group 0.000 claims description 5
- 241000710780 Bovine viral diarrhea virus 1 Species 0.000 claims description 4
- 241000710842 Japanese encephalitis virus Species 0.000 claims description 4
- 101800001554 RNA-directed RNA polymerase Proteins 0.000 claims description 4
- 241000710886 West Nile virus Species 0.000 claims description 4
- 125000002393 azetidinyl group Chemical group 0.000 claims description 4
- 229940079593 drug Drugs 0.000 claims description 4
- 125000002883 imidazolyl group Chemical group 0.000 claims description 4
- 239000008194 pharmaceutical composition Substances 0.000 claims description 4
- 125000003386 piperidinyl group Chemical group 0.000 claims description 4
- 125000003373 pyrazinyl group Chemical group 0.000 claims description 4
- 125000002098 pyridazinyl group Chemical group 0.000 claims description 4
- 125000004076 pyridyl group Chemical group 0.000 claims description 4
- 125000000714 pyrimidinyl group Chemical group 0.000 claims description 4
- 125000000719 pyrrolidinyl group Chemical group 0.000 claims description 4
- 125000002943 quinolinyl group Chemical group N1=C(C=CC2=CC=CC=C12)* 0.000 claims description 4
- 125000003507 tetrahydrothiofenyl group Chemical group 0.000 claims description 4
- 229940124597 therapeutic agent Drugs 0.000 claims description 4
- 125000001544 thienyl group Chemical group 0.000 claims description 4
- 101001023866 Arabidopsis thaliana Mannosyl-oligosaccharide glucosidase GCS1 Proteins 0.000 claims description 3
- 102000014150 Interferons Human genes 0.000 claims description 3
- 108010050904 Interferons Proteins 0.000 claims description 3
- 101800001014 Non-structural protein 5A Proteins 0.000 claims description 3
- 241000725177 Omsk hemorrhagic fever virus Species 0.000 claims description 3
- 241000907316 Zika virus Species 0.000 claims description 3
- 239000000134 cyclophilin inhibitor Substances 0.000 claims description 3
- 239000003623 enhancer Substances 0.000 claims description 3
- 125000001188 haloalkyl group Chemical group 0.000 claims description 3
- 241000725619 Dengue virus Species 0.000 claims description 2
- 241000710888 St. Louis encephalitis virus Species 0.000 claims description 2
- 241000710772 Yellow fever virus Species 0.000 claims description 2
- 239000003937 drug carrier Substances 0.000 claims description 2
- 206010014599 encephalitis Diseases 0.000 claims description 2
- 239000002773 nucleotide Substances 0.000 claims description 2
- 125000003729 nucleotide group Chemical group 0.000 claims description 2
- 239000000546 pharmaceutical excipient Substances 0.000 claims description 2
- 229940051021 yellow-fever virus Drugs 0.000 claims description 2
- 239000005557 antagonist Substances 0.000 claims 4
- KJTLQQUUPVSXIM-ZCFIWIBFSA-M (R)-mevalonate Chemical compound OCC[C@](O)(C)CC([O-])=O KJTLQQUUPVSXIM-ZCFIWIBFSA-M 0.000 claims 2
- 229940122806 Cyclophilin inhibitor Drugs 0.000 claims 2
- KJTLQQUUPVSXIM-UHFFFAOYSA-N DL-mevalonic acid Natural products OCCC(O)(C)CC(O)=O KJTLQQUUPVSXIM-UHFFFAOYSA-N 0.000 claims 2
- 101800001838 Serine protease/helicase NS3 Proteins 0.000 claims 2
- 229940124615 TLR 7 agonist Drugs 0.000 claims 2
- 230000003510 anti-fibrotic effect Effects 0.000 claims 2
- 239000003795 chemical substances by application Substances 0.000 claims 2
- 108700008776 hepatitis C virus NS-5 Proteins 0.000 claims 2
- 230000002443 hepatoprotective effect Effects 0.000 claims 2
- 229940079322 interferon Drugs 0.000 claims 2
- 230000036454 renin-angiotensin system Effects 0.000 claims 2
- 241000238876 Acari Species 0.000 claims 1
- 241000710912 Kunjin virus Species 0.000 claims 1
- 241000710908 Murray Valley encephalitis virus Species 0.000 claims 1
- 229940123066 Polymerase inhibitor Drugs 0.000 claims 1
- 125000003302 alkenyloxy group Chemical group 0.000 claims 1
- 125000000217 alkyl group Chemical group 0.000 claims 1
- 125000004641 (C1-C12) haloalkyl group Chemical group 0.000 abstract description 2
- 125000000171 (C1-C6) haloalkyl group Chemical group 0.000 abstract 1
- 229910052757 nitrogen Inorganic materials 0.000 description 13
- 208000015181 infectious disease Diseases 0.000 description 6
- 238000000034 method Methods 0.000 description 6
- 230000001684 chronic effect Effects 0.000 description 4
- 201000010099 disease Diseases 0.000 description 4
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 4
- 230000003612 virological effect Effects 0.000 description 4
- 125000004514 1,2,4-thiadiazolyl group Chemical group 0.000 description 3
- 125000001781 1,3,4-oxadiazolyl group Chemical group 0.000 description 3
- 125000004520 1,3,4-thiadiazolyl group Chemical group 0.000 description 3
- 241000282412 Homo Species 0.000 description 3
- 230000000840 anti-viral effect Effects 0.000 description 3
- 230000008030 elimination Effects 0.000 description 3
- 238000003379 elimination reaction Methods 0.000 description 3
- 125000000335 thiazolyl group Chemical group 0.000 description 3
- 125000001313 C5-C10 heteroaryl group Chemical group 0.000 description 2
- 241000710831 Flavivirus Species 0.000 description 2
- 241000711557 Hepacivirus Species 0.000 description 2
- 241001465754 Metazoa Species 0.000 description 2
- 241000710778 Pestivirus Species 0.000 description 2
- 241000710771 Tick-borne encephalitis virus Species 0.000 description 2
- 230000000694 effects Effects 0.000 description 2
- 208000010710 hepatitis C virus infection Diseases 0.000 description 2
- 230000002265 prevention Effects 0.000 description 2
- 238000002560 therapeutic procedure Methods 0.000 description 2
- HBAQYPYDRFILMT-UHFFFAOYSA-N 8-[3-(1-cyclopropylpyrazol-4-yl)-1H-pyrazolo[4,3-d]pyrimidin-5-yl]-3-methyl-3,8-diazabicyclo[3.2.1]octan-2-one Chemical class C1(CC1)N1N=CC(=C1)C1=NNC2=C1N=C(N=C2)N1C2C(N(CC1CC2)C)=O HBAQYPYDRFILMT-UHFFFAOYSA-N 0.000 description 1
- 208000031295 Animal disease Diseases 0.000 description 1
- 206010008631 Cholera Diseases 0.000 description 1
- 208000006154 Chronic hepatitis C Diseases 0.000 description 1
- 241000710777 Classical swine fever virus Species 0.000 description 1
- 208000001490 Dengue Diseases 0.000 description 1
- 206010012310 Dengue fever Diseases 0.000 description 1
- 229940124771 HCV-NS3 protease inhibitor Drugs 0.000 description 1
- 208000005176 Hepatitis C Diseases 0.000 description 1
- 102000006992 Interferon-alpha Human genes 0.000 description 1
- 108010047761 Interferon-alpha Proteins 0.000 description 1
- 201000005805 Murray valley encephalitis Diseases 0.000 description 1
- 241001494479 Pecora Species 0.000 description 1
- 206010041896 St. Louis Encephalitis Diseases 0.000 description 1
- 241000282898 Sus scrofa Species 0.000 description 1
- 108020000999 Viral RNA Proteins 0.000 description 1
- 208000003152 Yellow Fever Diseases 0.000 description 1
- 239000002253 acid Substances 0.000 description 1
- 230000001154 acute effect Effects 0.000 description 1
- 238000004458 analytical method Methods 0.000 description 1
- 208000007502 anemia Diseases 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- 238000012512 characterization method Methods 0.000 description 1
- 238000002512 chemotherapy Methods 0.000 description 1
- LXWYCLOUQZZDBD-LIYNQYRNSA-N csfv Chemical compound C([C@H](NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@@H](N)[C@@H](C)CC)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CO)C(=O)N[C@@H](CO)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCC(O)=O)C(O)=O)C1=CC=C(O)C=C1 LXWYCLOUQZZDBD-LIYNQYRNSA-N 0.000 description 1
- 208000025729 dengue disease Diseases 0.000 description 1
- 238000009472 formulation Methods 0.000 description 1
- 229940047124 interferons Drugs 0.000 description 1
- 239000000543 intermediate Substances 0.000 description 1
- 238000002955 isolation Methods 0.000 description 1
- 208000019423 liver disease Diseases 0.000 description 1
- 238000004519 manufacturing process Methods 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 229940127073 nucleoside analogue Drugs 0.000 description 1
- 230000002085 persistent effect Effects 0.000 description 1
- 238000002360 preparation method Methods 0.000 description 1
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 description 1
- 108090000623 proteins and genes Proteins 0.000 description 1
- 238000000746 purification Methods 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- 238000012552 review Methods 0.000 description 1
- 238000000926 separation method Methods 0.000 description 1
- 230000002269 spontaneous effect Effects 0.000 description 1
- 208000024891 symptom Diseases 0.000 description 1
- 238000003786 synthesis reaction Methods 0.000 description 1
- 238000012360 testing method Methods 0.000 description 1
- 229930192474 thiophene Natural products 0.000 description 1
- 150000003577 thiophenes Chemical class 0.000 description 1
- 229940044616 toll-like receptor 7 agonist Drugs 0.000 description 1
- 231100000419 toxicity Toxicity 0.000 description 1
- 230000001988 toxicity Effects 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
- C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
- C07D409/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/38—Heterocyclic compounds having sulfur as a ring hetero atom
- A61K31/381—Heterocyclic compounds having sulfur as a ring hetero atom having five-membered rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
- A61K31/4436—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a heterocyclic ring having sulfur as a ring hetero atom
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/19—Cytokines; Lymphokines; Interferons
- A61K38/21—Interferons [IFN]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
- C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
- C07D409/08—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a carbon chain containing alicyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Organic Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Epidemiology (AREA)
- General Chemical & Material Sciences (AREA)
- Virology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Oncology (AREA)
- Communicable Diseases (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Engineering & Computer Science (AREA)
- Zoology (AREA)
- Gastroenterology & Hepatology (AREA)
- Molecular Biology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Immunology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Agricultural Chemicals And Associated Chemicals (AREA)
- Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
- Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US29557610P | 2010-01-15 | 2010-01-15 | |
| US295576P | 2010-01-15 | ||
| US35348110P | 2010-06-10 | 2010-06-10 | |
| US353481P | 2010-06-10 | ||
| PCT/US2011/021335 WO2011088345A1 (en) | 2010-01-15 | 2011-01-14 | Inhibitors of flaviviridae viruses |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| ES2626150T3 true ES2626150T3 (es) | 2017-07-24 |
Family
ID=43538203
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ES11700988.6T Active ES2626150T3 (es) | 2010-01-15 | 2011-01-14 | Inhibidores de virus flaviviridae |
Country Status (27)
| Country | Link |
|---|---|
| US (2) | US8513298B2 (enExample) |
| EP (2) | EP2523950B1 (enExample) |
| JP (2) | JP5868872B2 (enExample) |
| KR (1) | KR101727776B1 (enExample) |
| CN (1) | CN102712633B (enExample) |
| AP (1) | AP3576A (enExample) |
| AR (1) | AR080001A1 (enExample) |
| AU (1) | AU2011205744B2 (enExample) |
| BR (1) | BR112012017382A2 (enExample) |
| CA (1) | CA2785567C (enExample) |
| CL (1) | CL2012001960A1 (enExample) |
| CR (1) | CR20120417A (enExample) |
| EA (1) | EA021196B1 (enExample) |
| EC (1) | ECSP12012104A (enExample) |
| ES (1) | ES2626150T3 (enExample) |
| IL (1) | IL220545B (enExample) |
| MX (1) | MX2012008211A (enExample) |
| NZ (1) | NZ600817A (enExample) |
| PE (1) | PE20130281A1 (enExample) |
| PL (1) | PL2523950T3 (enExample) |
| PT (1) | PT2523950T (enExample) |
| SG (2) | SG10201500298PA (enExample) |
| SI (1) | SI2523950T1 (enExample) |
| TW (1) | TWI491609B (enExample) |
| UY (1) | UY33183A (enExample) |
| WO (1) | WO2011088345A1 (enExample) |
| ZA (1) | ZA201205248B (enExample) |
Families Citing this family (29)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| KR20120051022A (ko) * | 2009-07-21 | 2012-05-21 | 길리애드 사이언시즈, 인코포레이티드 | 플라비비리데 바이러스의억제제 |
| CA2771124C (en) | 2009-09-09 | 2019-01-15 | Gilead Sciences, Inc. | Inhibitors of flaviviridae viruses |
| EA201290575A1 (ru) | 2010-01-15 | 2013-01-30 | Джилид Сайэнс, Инк. | Ингибиторы вирусов flaviviridae |
| TWI491609B (zh) * | 2010-01-15 | 2015-07-11 | Gilead Sciences Inc | 黃熱病毒科（Ｆｌａｖｉｖｉｒｉｄａｅ）病毒之抑制劑類 |
| TW201306841A (zh) * | 2010-12-20 | 2013-02-16 | Gilead Sciences Inc | 治療ｃ型肝炎病毒（ｈｃｖ）之方法 |
| DE102011003295A1 (de) * | 2011-01-28 | 2012-08-02 | Kiekert Ag | Kraftfahrzeugschloss |
| US8741946B2 (en) | 2011-07-13 | 2014-06-03 | Gilead Sciences, Inc. | Inhibitors of flaviviridae viruses |
| HRP20180237T4 (hr) * | 2011-09-16 | 2020-12-11 | Gilead Pharmasset Llc | Metode za liječenje hcv-a |
| CN103087052A (zh) * | 2011-10-31 | 2013-05-08 | 上海壹志医药科技有限公司 | 噻吩衍生物及其药物用途 |
| SI2859009T1 (sl) | 2012-06-08 | 2017-12-29 | Gilead Sciences, Inc. | Makrociklični inhibitorji flaviviridae virusov |
| AR091279A1 (es) | 2012-06-08 | 2015-01-21 | Gilead Sciences Inc | Inhibidores macrociclicos de virus flaviviridae |
| IN2014MN02652A (enExample) | 2012-06-08 | 2015-08-21 | Gilead Sciences Inc | |
| US8927741B2 (en) | 2012-08-17 | 2015-01-06 | Gilead Sciences, Inc. | Synthesis of an antiviral compound |
| US8759544B2 (en) * | 2012-08-17 | 2014-06-24 | Gilead Sciences, Inc. | Synthesis of an antiviral compound |
| US8841340B2 (en) * | 2012-08-17 | 2014-09-23 | Gilead Sciences, Inc. | Solid forms of an antiviral compound |
| EP2950786B1 (en) | 2013-01-31 | 2019-11-27 | Gilead Pharmasset LLC | Combination formulation of two antiviral compounds |
| US10190162B2 (en) | 2014-10-23 | 2019-01-29 | Complete Genomics, Inc. | Signal confinement sequencing (SCS) and nucleotide analogues for signal confinement sequencing |
| WO2016106050A1 (en) | 2014-12-26 | 2016-06-30 | Emory University | N4-hydroxycytidine and derivatives and anti-viral uses related thereto |
| US10328061B2 (en) | 2016-05-02 | 2019-06-25 | Florida State University Research Foundation, Inc. | Treatment of Zika virus infections using alpha-glucosidase inhibitors |
| CN109562113A (zh) | 2016-05-10 | 2019-04-02 | C4医药公司 | 用于靶蛋白降解的螺环降解决定子体 |
| CN109562107A (zh) | 2016-05-10 | 2019-04-02 | C4医药公司 | 用于靶蛋白降解的杂环降解决定子体 |
| WO2017197046A1 (en) | 2016-05-10 | 2017-11-16 | C4 Therapeutics, Inc. | C3-carbon linked glutarimide degronimers for target protein degradation |
| CN121974842A (zh) | 2016-05-10 | 2026-05-05 | C4医药公司 | 用于靶蛋白降解的胺连接的c3-戊二酰亚胺降解决定子体 |
| SI3464336T1 (sl) | 2016-06-01 | 2022-06-30 | Athira Pharma, Inc. | Spojine |
| EP4717317A3 (en) | 2017-06-20 | 2026-06-03 | C4 Therapeutics, Inc. | N/o-linked degrons and degronimers for protein degradation |
| RU2020116571A (ru) | 2017-12-07 | 2021-11-22 | Эмори Юниверсити | N4-гидроксицитидин и производные и связанные с этим противовирусные применения |
| CN108096562B (zh) * | 2017-12-25 | 2021-05-11 | 武汉百药联科科技有限公司 | 20s蛋白酶体抑制剂在制备治疗日本乙型脑炎病毒感染的药物中的用途 |
| EP4178955A1 (en) | 2020-07-11 | 2023-05-17 | Pfizer Inc. | Antiviral heteroaryl ketone derivatives |
| US11351149B2 (en) | 2020-09-03 | 2022-06-07 | Pfizer Inc. | Nitrile-containing antiviral compounds |
Family Cites Families (41)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US743729A (en) * | 1903-03-02 | 1903-11-10 | William Clark Kirk | Work-support for lathes. |
| US3533088A (en) * | 1967-10-31 | 1970-10-06 | Rca Corp | Control circuit for memory |
| US4714839A (en) * | 1986-03-27 | 1987-12-22 | Advanced Micro Devices, Inc. | Control circuit for disabling or enabling the provision of redundancy |
| US4721868A (en) * | 1986-09-23 | 1988-01-26 | Advanced Micro Devices, Inc. | IC input circuitry programmable for realizing multiple functions from a single input |
| JPH02146195A (ja) * | 1988-11-28 | 1990-06-05 | Nec Corp | 半導体記憶装置 |
| JPH03214500A (ja) * | 1990-01-18 | 1991-09-19 | Sony Corp | メモリ装置 |
| JP2575919B2 (ja) * | 1990-03-22 | 1997-01-29 | 株式会社東芝 | 半導体記憶装置の冗長回路 |
| US5959445A (en) * | 1995-09-29 | 1999-09-28 | Intel Corporation | Static, high-sensitivity, fuse-based storage cell |
| US5861421A (en) | 1995-12-21 | 1999-01-19 | Smithkline Beecham Corporation | 4,4-(disubstituted) cyclohexan-1-one monomers and related compounds |
| US6037799A (en) * | 1995-12-29 | 2000-03-14 | Stmicroelectronics, Inc. | Circuit and method for selecting a signal |
| US20050119332A1 (en) | 1998-03-12 | 2005-06-02 | Lone Jeppesen | Substituted thiophene compounds as modulators of protein tyrosine phosphatases (PTPases) |
| US20020002199A1 (en) | 1998-03-12 | 2002-01-03 | Lone Jeppesen | Modulators of protein tyrosine phosphatases (ptpases) |
| US6175261B1 (en) * | 1999-01-07 | 2001-01-16 | Texas Instruments Incorporated | Fuse cell for on-chip trimming |
| US6275063B1 (en) * | 1999-08-24 | 2001-08-14 | Micron Technology, Inc. | Method and apparatus for limited reprogrammability of fuse options using one-time programmable elements |
| US6353336B1 (en) * | 2000-03-24 | 2002-03-05 | Cypress Semiconductor Corp. | Electrical ID method for output driver |
| EP1395571A1 (en) | 2001-06-11 | 2004-03-10 | Shire Biochem Inc. | Compounds and methods for the treatment or prevention of flavivirus infections |
| EP2363396A1 (en) | 2001-06-11 | 2011-09-07 | Virochem Pharma Inc. | Thiophene derivatives as antiviral agents for flavivirus infection |
| KR100481179B1 (ko) * | 2002-09-10 | 2005-04-07 | 삼성전자주식회사 | 퓨즈를 구비한 회로 및 이를 이용한 반도체 장치 |
| JP3884374B2 (ja) * | 2002-12-06 | 2007-02-21 | 株式会社東芝 | 半導体装置 |
| ATE466856T1 (de) | 2002-12-10 | 2010-05-15 | Virochem Pharma Inc | Verbindungen und methoden zum behandeln oder vorbeugen von flavivirus infektionen |
| DE60332482D1 (de) * | 2002-12-10 | 2010-06-17 | Virochem Pharma Inc | Verbindungen und methoden zum behandeln oder vorbeugen von flavivirus infektionen |
| KR100569585B1 (ko) * | 2003-12-05 | 2006-04-10 | 주식회사 하이닉스반도체 | 내부 전원 드라이버 제어 회로 |
| DE10359791A1 (de) | 2003-12-19 | 2005-07-21 | Bayer Healthcare Ag | Substituierte Thiophene |
| WO2005081954A2 (en) | 2004-02-25 | 2005-09-09 | Wyeth | Inhibitors of protein tyrosine phosphatase 1b |
| WO2005095386A1 (en) * | 2004-03-30 | 2005-10-13 | Chiron Corporation | Substituted thiophene derivatives as anti-cancer agents |
| DE102004061746A1 (de) | 2004-12-22 | 2006-07-06 | Bayer Healthcare Ag | Alkinyl-substituierte Thiophene |
| DE102005028077A1 (de) | 2004-12-22 | 2006-07-13 | Aicuris Gmbh & Co. Kg | Alkinyl-substituierte Thiophene |
| JP5030947B2 (ja) * | 2005-05-13 | 2012-09-19 | ヴァイロケム・ファーマ・インコーポレーテッド | フラビウイルス感染の治療及び予防のための化合物及び方法 |
| CN101501215A (zh) | 2005-07-07 | 2009-08-05 | 阿什洛米克斯控股有限公司 | 用于诊断内毒素血症的多核苷酸标记基因及它们的表达 |
| GB0602046D0 (en) | 2006-02-01 | 2006-03-15 | Smithkline Beecham Corp | Compounds |
| AU2007214710A1 (en) | 2006-02-15 | 2007-08-23 | Sanofi-Aventis | Novel amino alcohol-substituted arylthienopyrimidinones, process for their preparation and their use as medicaments |
| SG176488A1 (en) | 2006-11-15 | 2011-12-29 | Virochem Pharma Inc | Thiophene analogues for the treatment or prevention of flavivirus infections |
| ATE524465T1 (de) | 2006-11-17 | 2011-09-15 | Glaxosmithkline Llc | 2-carboxy-thiophen-derivate als viruzide |
| WO2010065668A1 (en) | 2008-12-03 | 2010-06-10 | Presidio Pharmaceuticals, Inc. | Inhibitors of hcv ns5a |
| KR20120051022A (ko) * | 2009-07-21 | 2012-05-21 | 길리애드 사이언시즈, 인코포레이티드 | 플라비비리데 바이러스의억제제 |
| CA2771124C (en) | 2009-09-09 | 2019-01-15 | Gilead Sciences, Inc. | Inhibitors of flaviviridae viruses |
| EP2504329A1 (en) | 2009-11-25 | 2012-10-03 | Vertex Pharmaceuticals Incorporated | 5-alkynyl-thiophene-2-carboxylic acid derivatives and their use for the treatment or prevention of flavivirus infections |
| TWI491609B (zh) | 2010-01-15 | 2015-07-11 | Gilead Sciences Inc | 黃熱病毒科（Ｆｌａｖｉｖｉｒｉｄａｅ）病毒之抑制劑類 |
| EA201290575A1 (ru) * | 2010-01-15 | 2013-01-30 | Джилид Сайэнс, Инк. | Ингибиторы вирусов flaviviridae |
| JP2013529684A (ja) | 2010-06-28 | 2013-07-22 | バーテックス ファーマシューティカルズ インコーポレイテッド | フラビウイルス感染の処置または予防のための化合物および方法 |
| US8741946B2 (en) | 2011-07-13 | 2014-06-03 | Gilead Sciences, Inc. | Inhibitors of flaviviridae viruses |
-
2011
- 2011-01-14 TW TW100101437A patent/TWI491609B/zh active
- 2011-01-14 EP EP11700988.6A patent/EP2523950B1/en active Active
- 2011-01-14 US US13/007,150 patent/US8513298B2/en active Active
- 2011-01-14 NZ NZ600817A patent/NZ600817A/en not_active IP Right Cessation
- 2011-01-14 EP EP17160365.7A patent/EP3219713A1/en not_active Withdrawn
- 2011-01-14 JP JP2012549122A patent/JP5868872B2/ja active Active
- 2011-01-14 SG SG10201500298PA patent/SG10201500298PA/en unknown
- 2011-01-14 SI SI201131169A patent/SI2523950T1/sl unknown
- 2011-01-14 EA EA201290576A patent/EA021196B1/ru not_active IP Right Cessation
- 2011-01-14 AR ARP110100126A patent/AR080001A1/es unknown
- 2011-01-14 KR KR1020127021314A patent/KR101727776B1/ko active Active
- 2011-01-14 CN CN201180005975.8A patent/CN102712633B/zh active Active
- 2011-01-14 UY UY0001033183A patent/UY33183A/es not_active Application Discontinuation
- 2011-01-14 MX MX2012008211A patent/MX2012008211A/es active IP Right Grant
- 2011-01-14 ES ES11700988.6T patent/ES2626150T3/es active Active
- 2011-01-14 CA CA2785567A patent/CA2785567C/en active Active
- 2011-01-14 PT PT117009886T patent/PT2523950T/pt unknown
- 2011-01-14 SG SG2012051181A patent/SG182475A1/en unknown
- 2011-01-14 WO PCT/US2011/021335 patent/WO2011088345A1/en not_active Ceased
- 2011-01-14 PL PL11700988T patent/PL2523950T3/pl unknown
- 2011-01-14 PE PE2012000999A patent/PE20130281A1/es not_active Application Discontinuation
- 2011-01-14 AU AU2011205744A patent/AU2011205744B2/en not_active Ceased
- 2011-01-14 AP AP2012006414A patent/AP3576A/xx active
- 2011-01-14 BR BR112012017382A patent/BR112012017382A2/pt not_active Application Discontinuation
-
2012
- 2012-06-21 IL IL220545A patent/IL220545B/en not_active IP Right Cessation
- 2012-07-13 CL CL2012001960A patent/CL2012001960A1/es unknown
- 2012-07-13 ZA ZA2012/05248A patent/ZA201205248B/en unknown
- 2012-08-10 CR CR20120417A patent/CR20120417A/es unknown
- 2012-08-13 EC ECSP12012104 patent/ECSP12012104A/es unknown
-
2013
- 2013-07-11 US US13/939,695 patent/US9321753B2/en active Active
-
2015
- 2015-11-02 JP JP2015215450A patent/JP2016041732A/ja not_active Withdrawn
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| ES2561888T3 (es) | Derivados de ácido tiofeno-2-carboxílico útiles como inhibidores de virus Flaviviridae | |
| ES2659216T3 (es) | Métodos para el tratamiento del VHC | |
| CN1972696B (zh) | 用于治疗rna依赖性rna病毒感染的核苷氨基磷酸芳基酯 | |
| JP5539363B2 (ja) | インターフェロンおよびリバビリンとのｈｃｖｎｓ３プロテアーゼ阻害剤の組合せ | |
| JP2008531704A5 (enExample) | ||
| WO2011049988A2 (en) | Indazoles to treat flaviviridae virus infection | |
| JP2015098501A (ja) | ヌクレオシドポリメラーゼインヒビターと大環状プロテアーゼインヒビターの併用ならびにｃ型肝炎、肝臓線維症および肝臓機能障害の治療におけるその使用 | |
| JP2013517291A5 (enExample) | ||
| JP2011521903A5 (enExample) | ||
| JP2011518835A5 (enExample) | ||
| KR20070102741A (ko) | 플라비비리대 감염증을 치료하거나 예방하기 위한 조성물및 방법 | |
| HRP20140219T1 (hr) | Analozi karba-nukleozida za antivirusno lijeäśenje | |
| KR20110054056A (ko) | 마크로사이클릭 ｈｃｖ 저해제 및 뉴클레오시드의 상승적 배합물 | |
| ZA200206506B (en) | Method for the treatment or prevention of Flavivirus infections using nucleoside analogues. | |
| JP2015512860A5 (enExample) | ||
| JP2010508362A5 (enExample) | ||
| JP2012512169A5 (enExample) | ||
| JP2010510234A5 (enExample) | ||
| JP2012514606A (ja) | Ｈｃｖ治療のためのシクロスポリン誘導体およびヌクレオシドの配合 | |
| HRP20110637T1 (hr) | Metoda liječenja pacijenata sa hepatitisom c | |
| WO2010031832A9 (en) | Synergistic combinations of a macrocyclic inhibitor of hcv and a thiophene-2-carboxylic acid derivative | |
| ES2381410T3 (es) | Terapia de combinación paa el tratamiento de infecciones por VHC | |
| AU2004216485B2 (en) | Combined use of ribavirin and interferon beta in demyelinating diseases | |
| ES2402589T3 (es) | Agente profiláctico o terapéutico para enfermedad viral | |
| CA2967195A1 (en) | Long acting pharmaceutical compositions for hepatitis c |